| __timestamp | Ionis Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20140000 | 504755000 |
| Thursday, January 1, 2015 | 37173000 | 838526000 |
| Friday, January 1, 2016 | 48616000 | 1177697000 |
| Sunday, January 1, 2017 | 108488000 | 1320433000 |
| Monday, January 1, 2018 | 244622000 | 1556200000 |
| Tuesday, January 1, 2019 | 287000000 | 1834800000 |
| Wednesday, January 1, 2020 | 354000000 | 1346000000 |
| Friday, January 1, 2021 | 186000000 | 1824900000 |
| Saturday, January 1, 2022 | 151000000 | 2115900000 |
| Sunday, January 1, 2023 | 232600000 | 2631300000 |
| Monday, January 1, 2024 | 267474000 | 2954400000 |
Data in motion
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Regeneron Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc. have demonstrated contrasting approaches to SG&A cost management. From 2014 to 2023, Regeneron consistently reported higher SG&A expenses, peaking at approximately $2.63 billion in 2023. In contrast, Ionis maintained a more conservative approach, with expenses reaching around $354 million at their highest in 2020.
Regeneron's SG&A expenses grew by over 400% from 2014 to 2023, reflecting its aggressive expansion and investment in marketing and administrative capabilities. Meanwhile, Ionis's expenses increased by about 1,100% during the same period, indicating a strategic shift towards scaling operations. This data highlights the diverse strategies employed by these companies in navigating the biotech landscape, offering valuable insights for investors and industry analysts alike.
Comparing SG&A Expenses: AstraZeneca PLC vs Regeneron Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Summit Therapeutics Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Intra-Cellular Therapies, Inc. Trends and Insights
Regeneron Pharmaceuticals, Inc. vs Axsome Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Regeneron Pharmaceuticals, Inc. and Cytokinetics, Incorporated
Breaking Down SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs ImmunityBio, Inc.
Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Intra-Cellular Therapies, Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Insmed Incorporated or Ionis Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Sarepta Therapeutics, Inc. and Ionis Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Exelixis, Inc. and Ionis Pharmaceuticals, Inc.
Jazz Pharmaceuticals plc and Ionis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared